What is the 13F Pro Quality Score for PGEN?

13F Pro ranks PRECIGEN, INC. (PGEN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View PGEN's current score at https://13fpro.ai/research/PGEN (free sign-up required for the full ranking).

Which hedge funds own the most PGEN stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of PGEN include Patient Capital Management,, BlackRock,, STATE STREET. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/PGEN as soon as new 13F filings post.

Where does 13F Pro source PGEN data?

All PRECIGEN, INC. fundamentals and ownership data come directly from SEC EDGAR. PRECIGEN, INC. files with the SEC under CIK 1356090. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is PGEN in?

PRECIGEN, INC. (PGEN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is PGEN research updated on 13F Pro?

PGEN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

PRECIGEN, INC.(PGEN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1356090 PGEN stock profile & AI dashboard →

13F Pro Quality Score

38.6/100

Rank #2,004 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

97.5/100

Profitability

30.0/100

Balance Sheet

0.4/100

Earnings Quality

30.0/100

Free Cash Flow

30.0/100

Institutional Flow

47.4/100

Revenue Scale

30.0/100

Dilution Risk

3.0/100

PGEN Stock Analysis & AI Quality Score

AI stock analysis and institutional research for PRECIGEN, INC. (PGEN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PGEN at 38.6/100 on a 32-signal composite quality model, placing it at rank #2,004 of 2,879 stocks — the bottom half of the AI-ranked universe. PGEN scores in the top quartile across revenue growth (97.5). Areas of concern include balance sheet strength (0.4) and profitability (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 3.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), PRECIGEN, INC. reports quarterly revenue of $23.3M, net income of $-7.9M, free cash flow of $-44.1M. Top institutional holders of PGEN by reported 13-F value include Patient Capital Management,, BlackRock,, STATE STREET, based on the most recent SEC filings. PGEN trades on the Nasdaq exchange and files with the SEC under CIK 1356090. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PGEN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PRECIGEN, INC. directly from SEC EDGAR. PRECIGEN, INC.'s 13F Pro composite quality score has ranged between 8 and 42 since 2021, currently 38.6 — an improving long-term trajectory across 24 quarterly and live scoring snapshots.

✦

Fun facts about PRECIGEN, INC.

Quirks, history, and lore behind PGEN — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in Maryland · focused on genetic medicines.
2
The Numbers
A small-cap with revenues well under $100 million — most of it from collaborations and licenses rather than approved products. The pipeline is the asset.
3
The History
Born from a corporate spin-off in the late 2010s, it rebranded and refocused after shedding legacy businesses, pivoting hard into synthetic biology and gene-control platforms.
4
The Secret
Its crown jewel is a proprietary UltraCAR-T cell therapy platform, engineering patients' own immune cells to hunt down cancer with next-generation precision.
5
The Lore
The company traces roots to Intrexon, once dubbed a synthetic-biology superpower by the press — before it restructured, renamed, and narrowed its mission to oncology and infectious disease.
6
The Giveaway
Formerly known as Intrexon, it rebranded around a name evoking precision genetic engineering — and its Nasdaq ticker is four letters starting with PG.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$23.3M

Net Income

Q1 2026

$-7.9M

Free Cash Flow

Q1 2026

$-44.1M

D/E Ratio

Q1 2026

4.62

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-36.9% YoY

$3.9MFY 2024

FY21 $14.3MFY22 $26.9MFY23 $6.2MFY24 $3.9M

Net Income

-31.6% YoY

$-126.2MFY 2024

FY21 $-92.2MFY22 $28.3MFY23 $-95.9MFY24 $-126.2M

Operating Income

-35.4% YoY

$-135.0MFY 2024

FY21 —FY22 —FY23 $-99.8MFY24 $-135.0M

EPS (Diluted)

-20.5% YoY

$-0.47FY 2024

FY21 $-0.47FY22 $0.14FY23 $-0.39FY24 $-0.47

Total Assets

-3.8% YoY

$145.3MFY 2024

FY21 $359.9MFY22 $216.0MFY23 $151.0MFY24 $145.3M

Total Debt

$0.00FY 2024

FY21 $180.0MFY22 $129.7MFY23 $0.00FY24 $0.00

Op. Cash Flow

-1.9% YoY

$-68.2MFY 2024

FY21 $-55.8MFY22 $-65.0MFY23 $-66.9MFY24 $-68.2M

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$3.9M -36.9%	$6.2M -76.9%	$26.9M +88.6%	$14.3M -55.4%	$32.0M -64.7%	$90.7M
Net Income	$-126.2M -31.6%	$-95.9M -438.9%	$28.3M +130.7%	$-92.2M +45.9%	$-170.5M +47.1%	$-322.3M
Operating Income	$-135.0M -35.4%	$-99.8M	—	—	—	—
EPS (Diluted)	$-0.47 -20.5%	$-0.39 -378.6%	$0.14 +129.8%	$-0.47 +53.9%	$-1.02 +51.2%	$-2.09
Total Assets	$145.3M -3.8%	$151.0M -30.1%	$216.0M -40.0%	$359.9M +14.4%	$314.6M -31.0%	$455.8M
Total Debt	$0.00	$0.00 -100.0%	$129.7M -28.0%	$180.0M +4.5%	$172.2M -31.0%	$249.7M
Operating Cash Flow	$-68.2M -1.9%	$-66.9M -2.9%	$-65.0M -16.6%	$-55.8M +27.6%	$-77.0M +43.3%	$-135.9M

AI Insight: PGEN Ratio Trends

Q1 2026 marks first comprehensive profitability metric snapshot, revealing deeply negative returns across all efficiency measures with leverage spike.

• Q1 2026 operating margin -25.8%, net margin -34.1%; company burning cash operationally with no profitable quarter visible in dataset.

• ROE collapsed to -156.7% in Q1 2026; ROA deteriorated to -22.9% from -60.5% prior quarter, signaling accelerating shareholder value destruction.

• Debt-to-equity jumped to 4.62 in Q1 2026 from 2.22 in Q3 2025—leverage doubled while profitability metrics worsened sharply.

⚠ ROA swing from -60.5% (Q4 2025) to -22.9% (Q1 2026) suggests large one-off charge or seasonal swing; verify core cash burn trajectory.

⚠ D/E ratio 4.62 now exceeds Q4 2025 (4.46) despite negative earnings; refinancing risk elevated if debt covenants stressed.

Get alerted when PGEN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for PRECIGEN, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of PGEN

Patient Capital Management, LLC
$69.0M17,817,387 sh
BlackRock, Inc.
$58.9M15,223,191 sh
STATE STREET CORP
$42.1M10,890,124 sh
VANGUARD CAPITAL MANAGEMENT LLC
$27.7M7,148,996 sh
Diametric Capital, LP
$26.3M6,801,788 sh
Point72 Asset Management, L.P.
$25.7M6,644,361 sh
TANG CAPITAL MANAGEMENT LLC
$24.8M6,417,500 sh
GEODE CAPITAL MANAGEMENT, LLC
$17.9M4,613,429 sh
Occam Crest Management LP
$16.5M4,269,051 sh
IRIDIAN ASSET MANAGEMENT LLC/CT
$13.9M3,592,730 sh

Fund	Value	Shares
Patient Capital Management, LLC	$69.0M	17,817,387
BlackRock, Inc.	$58.9M	15,223,191
STATE STREET CORP	$42.1M	10,890,124
VANGUARD CAPITAL MANAGEMENT LLC	$27.7M	7,148,996
Diametric Capital, LP	$26.3M	6,801,788
Point72 Asset Management, L.P.	$25.7M	6,644,361
TANG CAPITAL MANAGEMENT LLC	$24.8M	6,417,500
GEODE CAPITAL MANAGEMENT, LLC	$17.9M	4,613,429
Occam Crest Management LP	$16.5M	4,269,051
IRIDIAN ASSET MANAGEMENT LLC/CT	$13.9M	3,592,730

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put PGEN on your watchlist

Track score changes the day PRECIGEN, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is PGEN a good stock to buy?

13F Pro's AI-powered analysis of PRECIGEN, INC. (PGEN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PGEN are available on the PGEN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own PGEN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PGEN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of PRECIGEN, INC.'s investment landscape.